Glypican-1 nanoliposomes for potentiating growth factor activity in therapeutic angiogenesis

Biomaterials

Volumn 94, Issue , 2016, Pages 45-56

  Monteforte, Anthony J ^a   Lam, Brian ^a   Das, Subhamoy ^a   Mukhopadhyay, Somshuvra ^b   Wright, Catherine S ^c   Martin, Patricia E ^c   Dunn, Andrew K ^a   Baker, Aaron B ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

Angiogenesis; Fibroblast growth factor 2 (FGF 2); Glypican 1; Ischemia; Neovascularization; Peripheral arterial disease; Proteoliposomes; Vascular endothelial growth factor (VEGF)

Indexed keywords

BLOOD VESSELS; CELL CULTURE; CELL ENGINEERING; CELL PROLIFERATION; DISEASE CONTROL; ENDOTHELIAL CELLS; MAMMALS; TISSUE;

ANGIOGENESIS; FIBROBLAST GROWTH FACTOR-2; GLYPICAN-1; ISCHEMIA; NEO-VASCULARIZATION; PERIPHERAL ARTERIAL DISEASE; PROTEOLIPOSOMES; VASCULAR ENDOTHELIAL GROWTH FACTOR;

DISEASES;

ALGINIC ACID; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GLYPICAN 1; GLYPISOME; GROWTH FACTOR; NANOCARRIER; RAB PROTEIN; RAB11 PROTEIN; RAB7 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; GLUCURONIC ACID; GLYPICAN; HEXURONIC ACID; LIPOSOME; NANOPARTICLE; PROTEIN KINASE B; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ENDOTHELIUM CELL; FEMALE; HINDLIMB; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEG BLOOD FLOW; LIMB ISCHEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; VERY ELDERLY; ANIMAL; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOSOME; EXPERIMENTAL DIABETES MELLITUS; HEK293 CELL LINE; HELA CELL LINE; ISCHEMIA; KINETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ALGINATES; ANIMALS; BLOOD VESSELS; CELL MOVEMENT; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; ENDOSOMES; FIBROBLAST GROWTH FACTOR 2; GLUCURONIC ACID; GLYPICANS; HEK293 CELLS; HELA CELLS; HEXURONIC ACIDS; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; KINETICS; LIPOSOMES; MICE, OBESE; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84963620727     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.048     Document Type: Article

References (62)

1. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. 2007, 45(Suppl. S):S5-S67.
2. Udelson J.E., Dilsizian V., Laham R.J., Chronos N., Vansant J., Blais M., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000, 102:1605-1610.
3. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
4. Lederman R.J., Tenaglia A.N., Anderson R.D., Hermiller J.B., Rocha-Singh K., Mendelsohn F.O., et al. Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. Am. J. Cardiol. 2001, 88:192-195. A6-7.
5. Rajagopalan S., Mohler E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933-1938.
6. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002, 105:1291-1297.
7. Kusumanto Y.H., van Weel V., Mulder N.H., Smit A.J., van den Dungen J.J., Hooymans J.M., et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 2006, 17:683-691.
8. Comerota A.J., Throm R.C., Miller K.A., Henry T., Chronos N., Laird J., et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J. Vasc. Surg. 2002, 35:930-936.
9. Belch J., Hiatt W.R., Baumgartner I., Driver I.V., Nikol S., Norgren L., et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011, 377:1929-1937.
10. Shigematsu H., Yasuda K., Iwai T., Sasajima T., Ishimaru S., Ohashi Y., et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010, 17:1152-1161.
11. Creager M.A., Olin J.W., Belch J.J., Moneta G.L., Henry T.D., Rajagopalan S., et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011, 124:1765-1773.
12. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105:788-793.
13. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107:1359-1365.
14. Annex B.H. Therapeutic angiogenesis for critical limb ischaemia. Nat. Rev. Cardiol. 2013, 10:387-396.
15. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am. J. Cardiol. 1995, 75:894-903.
16. Das S., Singh G., Baker A.B. Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system. Biomaterials 2014, 35:196-205.
17. Chen G., Wang D., Vikramadithyan R., Yagyu H., Saxena U., Pillarisetti S., et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004, 43:4971-4977.
18. Wang F., Kim M.S., Puthanveetil P., Kewalramani G., Deppe S., Ghosh S., et al. Endothelial heparanase secretion after acute hypoinsulinemia is regulated by glucose and fatty acid. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1108-H1116.
19. Zhang D., Wan A., Chiu A.P., Wang Y., Wang F., Neumaier K., et al. Hyperglycemia-induced secretion of endothelial heparanase stimulates a vascular endothelial growth factor autocrine network in cardiomyocytes that promotes recruitment of lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 2013 Dec, 33(12):2830-2838.
20. Baker A.B., Chatzizisis Y.S., Beigel R., Jonas M., Stone B.V., Coskun A.U., et al. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 2010, 213:436-442.
21. Osterholm C., Folkersen L., Lengquist M., Ponten F., Renne T., Li J., et al. Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 2013, 226:67-73.
22. Blich M., Golan A., Arvatz G., Sebbag A., Shafat I., Sabo E., et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler. Thromb. Vasc. Biol. 2013, 33:e56-65.
23. Baker A.B., Groothuis A., Jonas M., Ettenson D.S., Shazly T., Zcharia E., et al. Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circulation Res. 2009, 104:380-387.
24. Baker A.B., Gibson W.J., Kolachalama V.B., Golomb M., Indolfi L., Spruell C., et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J. Am. Coll. Cardiol. 2012, 59:1551-1560.
25. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999, 5:793-802.
26. Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J., Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 1999, 5:803-809.
27. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
28. Yang Y., Macleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
29. Paulick M.G., Bertozzi C.R. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008, 47:6991-7000.
30. Murakami M., Kambe T., Shimbara S., Yamamoto S., Kuwata H., Kudo I. Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway. J. Biol. Chem. 1999, 274:29927-29936.
31. Marois E., Mahmoud A., Eaton S. The endocytic pathway and formation of the wingless morphogen gradient. Development 2006, 133:307-317.
32. Gallet A., Staccini-Lavenant L., Therond P.P. Cellular trafficking of the glypican Dally-like is required for full-strength Hedgehog signaling and wingless transcytosis. Dev. Cell 2008, 14:712-725.
33. Beckett K., Franch-Marro X., Vincent J.P. Glypican-mediated endocytosis of Hedgehog has opposite effects in flies and mice. Trends Cell Biol. 2008, 18:360-363.
34. Christianson H.C., Svensson K.J., van Kuppevelt T.H., Li J.P., Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17380-17385.
35. Ledin J., Staatz W., Li J.P., Gotte M., Selleck S., Kjellen L., et al. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 2004, 279:42732-42741.
36. Kreuger J., Perez L., Giraldez A.J., Cohen S.M. Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity. Dev. Cell 2004, 7:503-512.
37. Gutierrez J., Cabrera D., Brandan E. Glypican-1 regulates myoblast response to HGF via Met in a lipid raft-dependent mechanism: effect on migration of skeletal muscle precursor cells. Skelet. Muscle 2014, 4:5.
38. Chamorro-Jorganes A., Araldi E., Rotllan N., Cirera-Salinas D., Suarez Y. Autoregulation of glypican-1 by intronic microRNA-149 fine tunes the angiogenic response to FGF2 in human endothelial cells. J. Cell Sci. 2014, 127:1169-1178.
39. Dwivedi P.P., Grose R.H., Filmus J., Hii C.S., Xian C.J., Anderson P.J., et al. Regulation of bone morphogenetic protein signalling and cranial osteogenesis by Gpc1 and Gpc3. Bone 2013, 55:367-376.
40. Kleeff J., Ishiwata T., Kumbasar A., Friess H., Buchler M.W., Lander A.D., et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 1998, 102:1662-1673.
41. Su G., Meyer K., Nandini C.D., Qiao D., Salamat S., Friedl A. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am. J. Pathol. 2006, 168:2014-2026.
42. Qiao D., Meyer K., Mundhenke C., Drew S.A., Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J. Biol. Chem. 2003, 278:16045-16053.
43. Theocharis A.D., Skandalis S.S., Tzanakakis G.N., Karamanos N.K. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010, 277:3904-3923.
44. Qiao D., Meyer K., Friedl A. Glypican 1 stimulates s phase entry and DNA replication in human glioma cells and normal astrocytes. Mol. Cell. Biol. 2013, 33:4408-4421.
45. Gengrinovitch S., Berman B., David G., Witte L., Neufeld G., Ron D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J. Biol. Chem. 1999, 274:10816-10822.
46. Jen Y.H., Musacchio M., Lander A.D. Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural Dev. 2009, 4:33.
47. Fico A., Maina F., Dono R. Fine-tuning of cell signaling by glypicans. Cell. Mol. Life Sci. CMLS 2011, 68:923-929.
48. Aikawa T., Whipple C.A., Lopez M.E., Gunn J., Young A., Lander A.D., et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Invest. 2008, 118:89-99.
49. Qiao D., Meyer K., Friedl A. Glypican-1 stimulates Skp2 autoinduction loop and G1/S transition in endothelial cells. J. Biol. Chem. 2012, 287:5898-5909.
50. Mukhopadhyay S., Linstedt A.D. Identification of a gain-of-function mutation in a Golgi P-type ATPase that enhances Mn2+ efflux and protects against toxicity. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:858-863.
51. Chen W., Feng Y., Chen D., Wandinger-Ness A. Rab11 is required for trans-golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Mol. Biol. Cell. 1998, 9:3241-3257.
52. Jang E., Albadawi H., Watkins M.T., Edelman E.R., Baker A.B. Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1679-1684.
53. Voyvodic P.L., Min D., Liu R., Williams E., Chitalia V., Dunn A.K., et al. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J. Biol. Chem. 2014, 289:9547-9559.
54. Laham R.J., Rezaee M., Post M., Novicki D., Sellke F.W., Pearlman J.D., et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J. Pharmacol. Exp. Ther. 2000, 292:795-802.
55. Baffour R., Berman J., Garb J.L., Rhee S.W., Kaufman J., Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J. Vasc. Surg. 1992, 16:181-191.
56. Cao R., Eriksson A., Kubo H., Alitalo K., Cao Y., Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circulation Res. 2004, 94:664-670.
57. Elfenbein A., Lanahan A., Zhou T.X., Yamasaki A., Tkachenko E., Matsuda M., et al. Syndecan 4 regulates FGFR1 signaling in endothelial cells by directing macropinocytosis. Sci. Signal. 2012, 5:ra36.
58. Mani K., Cheng F., Fransson L.A. Constitutive and vitamin C-induced, NO-catalyzed release of heparan sulfate from recycling glypican-1 in late endosomes. Glycobiology 2006, 16:1251-1261.
59. Jean S., Mikryukov A., Tremblay M.G., Baril J., Guillou F., Bellenfant S., et al. Extended-synaptotagmin-2 mediates FGF receptor endocytosis and ERK activation in vivo. Dev. Cell 2010, 19:426-439.
60. Gutierrez J., Brandan E. A novel mechanism of sequestering fibroblast growth factor 2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Mol. Cell. Biol. 2010, 30:1634-1649.
61. Shin J., McFarland D.C., Velleman S.G. Heparan sulfate proteoglycans, syndecan-4 and glypican-1, differentially regulate myogenic regulatory transcription factors and paired box 7 expression during turkey satellite cell myogenesis: implications for muscle growth. Poult. Sci. 2012, 91:201-207.
62. Slovut D.P., Sullivan T.M. Critical limb ischemia: medical and surgical management. Vasc. Med. 2008, 13:281-291.